Strategic IP Support since 1997
Recent Insights & News
Build, Buy or Licence? What Bayer’s Hybrid Wheat Deal Teaches About IP Licensing Strategy
Some assets cannot be built on any timeline a budget can shorten. When that is true, the choice is no longer build, buy or licence. It is licence, or stay out. Bayer’s move into hybrid wheat this year is a clean example, and a useful test of any IP licensing strategy. The world’s largest seed…
The Five-Year IP Roadmap Is Over: How to Build an IP Strategy for a Future You Can’t Predict
Long-lived patents, an AI-shifted landscape: why a fixed filing roadmap fails, and the three decision rules an IP strategy needs instead.
Your Patent Expiry Date Is the Wrong Number: What Loss of Exclusivity Actually Looks Like
Most boards plan around a single date. The patent expires, competitors arrive, the revenue line falls off a ledge. That model is tidy, it sits in the forecast, and for high-value products it is usually wrong. A recent analysis on DrugPatentWatch works through the loss-of-exclusivity histories of Revlimid, Humira, Eliquis and Keytruda and finds no…
Walking Away From a Brand Doesn’t Always Mean You’ve Let It Go
Intellectual property rights don’t dissolve the moment you stop paying attention to them. That’s the thread running through several developments last week, and it’s worth more attention than most companies give it, because the moment you decide to stop using a mark, retire a product line, or settle a patent fight is precisely the moment…
When Everything Is Urgent, Your IP Portfolio Decides Itself: Three Questions to Pressure-Test Your IP Strategy
Most IP portfolios are not shaped by strategy. They are shaped by whatever was urgent that week. Renewals get paid because the deadline arrived. Examination responses get filed because the clock was running. Meanwhile, the decisions that actually determine the value of an intellectual property portfolio – what to stop protecting, which jurisdictions no longer…
